We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Oracle, Merck, Union Pacific, CVD Equipment and Koil Energy Solutions
Read MoreHide Full Article
For Immediate Release
Chicago, IL – September 9, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Oracle Corp. (ORCL - Free Report) , Merck & Co., Inc. (MRK - Free Report) , Union Pacific Corp. (UNP - Free Report) , CVD Equipment Corp. (CVV - Free Report) and Koil Energy Solutions, Inc. (KLNG - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Stock Reports for Oracle, Merck and Union Pacific
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Oracle Corp., Merck & Co., Inc. and Union Pacific Corp., as well as two micro-cap stocks CVD Equipment Corp. and Koil Energy Solutions, Inc.. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
Shares of Oracle have gained +10.8% over the past six months against the Zacks Computer - Software industry's gain of +16.4%. The company's cloud infrastructure business demonstrates accelerating revenue growth, supported by strategic partnerships and competitive pricing that attract enterprise workload migrations.
AI-optimized database capabilities provide technological differentiation, while record fiscal 2026 operating cash flow of $32 billion enables sustained infrastructure investments. The integrated solutions strategy strengthens customer retention and drives cross-selling opportunities.
However, competition from hyperscalers remains intense, potentially pressuring margins. The ongoing transition from license revenue to subscription models creates near-term earnings volatility. Q1 fiscal 2027 guidance indicates total revenue growth of 27-29%, but execution risks around data center capacity expansion and funding requirements warrant monitoring.
Merck's shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past six months (+29.1% vs. +14%). The company's blockbuster drug, Keytruda, and new products have been driving sales. Animal Health is also contributing to growth. Though Keytruda will lose patent exclusivity in 2028, its sales are expected to remain strong until then.
Recent M&A deals have strengthened Merck's pipeline while its late-stage pipeline and new launches are gaining traction. This progress has increased confidence that Merck can maintain growth even after Keytruda loses exclusivity.
However, it faces several near-term challenges, including persistent challenges for Gardasil, potential competition for Keytruda, and rising competitive and generic pressure on some of its drugs. Also, estimates have declined recently due to costs related to its various M&A deals.
Shares of Union Pacific have outperformed the Zacks Transportation - Rail industry over the past six months (+15.5% vs. +15%). The company remains a high-quality rail franchise with a balanced risk-reward profile. Domestic intermodal growth, reliable service and productivity gains support volume capture across an uneven freight market. Pricing continues to exceed inflation, while cash generation and lower leverage support investment and dividend growth.
Management's improved earnings outlook reflects continued operating discipline. The proposed Norfolk Southern combination could broaden the network and improve long-term service, with regulatory commitments marking progress.
Still, freight demand remains mixed, coal and some industrial markets are soft, and fuel and labor costs can pressure margins. The merger also brings approval, financing, integration and dilution risks, while buybacks remain paused. These offsets support the Neutral recommendation.
CVD Equipment's shares have outperformed the Zacks Manufacturing - General Industrial industry over the past six months (+81.9% vs. -5%). This microcap company with a market capitalization of $45.67 million, has an investment case resting on its exposure to opportunities in ceramic matrix composites (CMCs), advanced battery materials, silicon carbide (SiC) applications and industrial and nuclear markets. Its installed equipment base provides scope for recurring aftermarket revenues as customer utilization rises.
Operational restructuring and the SDC divestiture have strengthened financial flexibility and created a leaner platform for future growth. However, the outlook remains tempered by volatile system bookings, customer concentration, weak SiC demand, elevated R&D spending and dependence on successful commercialization of newer products.
The valuation implies that investors continue to discount execution and demand risks. This could provide upside if order momentum and revenue visibility improve, but sustained weakness in bookings may limit rerating potential.
Shares of Koil Energy Solutions have outperformed the Zacks Alternative Energy - Other industry over the past six months (+37.6% vs. -9.8%). This microcap company with a market capitalization of $42.21 million saw its first-half 2026 results highlight strengthening growth and operating leverage, with revenues up 67% and operating income improving to $1 million from a year-ago loss.
Momentum is being driven by higher fixed-price and service revenues, meaningful contributions from new customers, expanding carousel rental activity and entry into Brazil. Broader exposure across West Africa, the Middle East and Asia Pacific, along with healthy subsea tieback and maintenance demand, further supports the growth outlook.
However, cash conversion remains weak, as higher receivables pushed operating cash flow negative, while rising capital spending and borrowing increase liquidity and financing risks. Results also depend heavily on a few large projects, making revenues vulnerable to execution delays and uneven recognition. Valuation is mixed, with EV/sales below industry levels but EV/EBITDA elevated.
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
View the Zacks #1 Rank List
Image: Bigstock
The Zacks Analyst Blog Highlights Oracle, Merck, Union Pacific, CVD Equipment and Koil Energy Solutions
For Immediate Release
Chicago, IL – September 9, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Oracle Corp. (ORCL - Free Report) , Merck & Co., Inc. (MRK - Free Report) , Union Pacific Corp. (UNP - Free Report) , CVD Equipment Corp. (CVV - Free Report) and Koil Energy Solutions, Inc. (KLNG - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Stock Reports for Oracle, Merck and Union Pacific
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Oracle Corp., Merck & Co., Inc. and Union Pacific Corp., as well as two micro-cap stocks CVD Equipment Corp. and Koil Energy Solutions, Inc.. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> Canadian Tariffs Hit $20B in U.S. Imports
Today's Featured Research Reports
Shares of Oracle have gained +10.8% over the past six months against the Zacks Computer - Software industry's gain of +16.4%. The company's cloud infrastructure business demonstrates accelerating revenue growth, supported by strategic partnerships and competitive pricing that attract enterprise workload migrations.
AI-optimized database capabilities provide technological differentiation, while record fiscal 2026 operating cash flow of $32 billion enables sustained infrastructure investments. The integrated solutions strategy strengthens customer retention and drives cross-selling opportunities.
However, competition from hyperscalers remains intense, potentially pressuring margins. The ongoing transition from license revenue to subscription models creates near-term earnings volatility. Q1 fiscal 2027 guidance indicates total revenue growth of 27-29%, but execution risks around data center capacity expansion and funding requirements warrant monitoring.
(You can read the full research report on Oracle here >>>)
Merck's shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past six months (+29.1% vs. +14%). The company's blockbuster drug, Keytruda, and new products have been driving sales. Animal Health is also contributing to growth. Though Keytruda will lose patent exclusivity in 2028, its sales are expected to remain strong until then.
Recent M&A deals have strengthened Merck's pipeline while its late-stage pipeline and new launches are gaining traction. This progress has increased confidence that Merck can maintain growth even after Keytruda loses exclusivity.
However, it faces several near-term challenges, including persistent challenges for Gardasil, potential competition for Keytruda, and rising competitive and generic pressure on some of its drugs. Also, estimates have declined recently due to costs related to its various M&A deals.
(You can read the full research report on Merck here >>>)
Shares of Union Pacific have outperformed the Zacks Transportation - Rail industry over the past six months (+15.5% vs. +15%). The company remains a high-quality rail franchise with a balanced risk-reward profile. Domestic intermodal growth, reliable service and productivity gains support volume capture across an uneven freight market. Pricing continues to exceed inflation, while cash generation and lower leverage support investment and dividend growth.
Management's improved earnings outlook reflects continued operating discipline. The proposed Norfolk Southern combination could broaden the network and improve long-term service, with regulatory commitments marking progress.
Still, freight demand remains mixed, coal and some industrial markets are soft, and fuel and labor costs can pressure margins. The merger also brings approval, financing, integration and dilution risks, while buybacks remain paused. These offsets support the Neutral recommendation.
(You can read the full research report on Union Pacific here >>>)
CVD Equipment's shares have outperformed the Zacks Manufacturing - General Industrial industry over the past six months (+81.9% vs. -5%). This microcap company with a market capitalization of $45.67 million, has an investment case resting on its exposure to opportunities in ceramic matrix composites (CMCs), advanced battery materials, silicon carbide (SiC) applications and industrial and nuclear markets. Its installed equipment base provides scope for recurring aftermarket revenues as customer utilization rises.
Operational restructuring and the SDC divestiture have strengthened financial flexibility and created a leaner platform for future growth. However, the outlook remains tempered by volatile system bookings, customer concentration, weak SiC demand, elevated R&D spending and dependence on successful commercialization of newer products.
The valuation implies that investors continue to discount execution and demand risks. This could provide upside if order momentum and revenue visibility improve, but sustained weakness in bookings may limit rerating potential.
(You canread the full research report on CVD Equipment here >>>)
Shares of Koil Energy Solutions have outperformed the Zacks Alternative Energy - Other industry over the past six months (+37.6% vs. -9.8%). This microcap company with a market capitalization of $42.21 million saw its first-half 2026 results highlight strengthening growth and operating leverage, with revenues up 67% and operating income improving to $1 million from a year-ago loss.
Momentum is being driven by higher fixed-price and service revenues, meaningful contributions from new customers, expanding carousel rental activity and entry into Brazil. Broader exposure across West Africa, the Middle East and Asia Pacific, along with healthy subsea tieback and maintenance demand, further supports the growth outlook.
However, cash conversion remains weak, as higher receivables pushed operating cash flow negative, while rising capital spending and borrowing increase liquidity and financing risks. Results also depend heavily on a few large projects, making revenues vulnerable to execution delays and uneven recognition. Valuation is mixed, with EV/sales below industry levels but EV/EBITDA elevated.
(You can read the full research report on Koil Energy Solutions here >>>)
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.